EverolimusHOUGHTON, Peter J.Clinical cancer research (Print). 2010, Vol 16, Num 5, pp 1368-1372, issn 1078-0432, 5 p.Article

Temsirolimus, an Inhibitor of Mammalian Target of RapamycinRINI, Brian I.Clinical cancer research. 2008, Vol 14, Num 5, pp 1286-1290, issn 1078-0432, 5 p.Article

Preclinical evidences suggest new treatment options for endocrine disorders : Pasireotide (SOM230) and Everolimus (RAD001)SCHMID, H. A.Annales d'endocrinologie. 2008, Vol 69, Num 2, pp 162-163, issn 0003-4266, 2 p.Conference Paper

Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRQINGSONG LIU; CHUNXIAO XU; ERCAN, Dalia et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 8, pp 2574-2586, issn 0008-5472, 13 p.Article

Inhibiteurs de mTOR: de l'explication biologique à l'application thérapeutique en hématologie = m-TOR inhibitors: biology and use in the treatment of haematological diseasesBALSAT, Marie; CORNILLON, Jérôme.Bulletin du cancer. 2011, Vol 98, Num 8, pp 935-943, issn 0007-4551, 9 p.Article

Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing ConsiderationsBONI, Joseph P; HUG, Bruce; LEISTER, Cathie et al.Seminars in oncology. 2009, Vol 36, Num 6, issn 0093-7754, S18-S25, SUP3Article

The Macrolide Everolimus Forms an Unusual Metabolite in Animals and Humans : Identification of a Phosphocholine EsterZOLLINGER, Markus; SAYER, Claudia; DANNECKER, Robert et al.Drug metabolism and disposition. 2008, Vol 36, Num 8, pp 1457-1460, issn 0090-9556, 4 p.Article

The Impact of mTOR Inhibitors on the Development of MalignancyGEISSLER, E. K.Transplantation proceedings. 2008, Vol 40, Num 10, issn 0041-1345, S32-S35, SUPConference Paper

NVP-BEZ235, a Dual P13K/mTOR Inhibitor, Prevents P13K Signaling and Inhibits the Growth of Cancer Cells with Activating P13K MutationsSERRA, Violeta; MARKMAN, Ben; MAIRA, Michel et al.Cancer research (Chicago, Ill.). 2008, Vol 68, Num 19, pp 8022-8030, issn 0008-5472, 9 p.Article

Sirolimus (rapamycin) : From the soil of Easter Island to a bright futurePAGHDAL, Kapila V; SCHWARTZ, Robert A.Journal of the American Academy of Dermatology. 2007, Vol 57, Num 6, pp 1046-1050, issn 0190-9622, 5 p.Article

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase InhibitorMALLON, Robert; FELDBERG, Larry R; HOLLANDER, Irwin et al.Clinical cancer research (Print). 2011, Vol 17, Num 10, pp 3193-3203, issn 1078-0432, 11 p.Article

Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical TrialsDANCEY, Janet E; CURIEL, Rafael; PURVIS, Joseph et al.Seminars in oncology. 2009, Vol 36, Num 6, issn 0093-7754, S46-S58, SUP3Article

Corneal Permeation Studies of Everolimus MicroemulsionBASPINAR, Yuecel; BERTELMANN, Eckart; PLEYER, Uwe et al.Journal of ocular pharmacology and therapeutics. 2008, Vol 24, Num 4, pp 399-402, issn 1080-7683, 4 p.Article

Rapamycin prevents thyroid hormone-induced cardiac hypertrophyKUZMAN, James A; O'CONNELL, Timothy D; GERDES, A. Martin et al.Endocrinology (Philadelphia). 2007, Vol 148, Num 7, pp 3477-3484, issn 0013-7227, 8 p.Article

Dedicated everolimus-eluting side branch access system: XIENCE SBASOROP, Oana; HATTEN, Thomas R; VAN BEUSEKOM, Heleen M. M et al.EuroIntervention. 2010, Vol 6, issn 1774-024X, J155-J160, SUPJArticle

Combined SFK/mTOR Inhibition Prevents Rapamycin-Induced Feedback Activation of AKT and Elicits Efficient Tumor RegressionYORI, Jennifer L; LOZADA, Kristen L; SEACHRIST, Darcie D et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 17, pp 4762-4771, issn 0008-5472, 10 p.Article

The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma CellsHAYMAN, Thomas J; WAHBA, Amy; RATH, Barbara H et al.Clinical cancer research (Print). 2014, Vol 20, Num 1, pp 110-119, issn 1078-0432, 10 p.Article

Can the Risk of Skin Cancer After Transplantation Be Reduced by mTOR Inhibitors?CARROLL, Robert P; CHAPMAN, Jeremy R.American journal of kidney diseases. 2013, Vol 61, Num 5, pp 698-700, issn 0272-6386, 3 p.Article

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical ExperienceYAO, James C; PHAN, Alexandria T; JEHL, Valentine et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 5, pp 1449-1453, issn 0008-5472, 5 p.Article

Identification of two novel inhibitors of mTOR signaling pathway based on high content screeningJUMING YAN; HONGYU ZHOU; LINGMEI KONG et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 4, pp 799-808, issn 0344-5704, 10 p.Article

mTOR Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor AngiogenesisROY, Debasmita; SIN, Sang-Hoon; DITTMER, Dirk P et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 7, pp 2235-2246, issn 0008-5472, 12 p.Article

Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trialBERK, Lori; MITA, Monica M; KREISBERG, Jeff et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 5, pp 1369-1377, issn 0344-5704, 9 p.Article

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)HOLT, Sarah V; LOGIE, Armelle; WILKINSON, Robert W et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 7, pp 1804-1813, issn 0008-5472, 10 p.Article

Everolimus Triggers Cytokine Release by Macrophages: Rationale for Stents Eluting Everolimus and a GlucocorticoidMARTINET, Wim; VERHEYE, Stefan; DE MEYER, Inge et al.Arteriosclerosis, thrombosis, and vascular biology. 2012, Vol 32, Num 5, pp 1228-1235, issn 1079-5642, 8 p.Article

Impact of Rapamycin on Peritoneal Fibrosis and Transport FunctionXU, T; XIE, Jy; WANG, Wm et al.Blood purification. 2012, Vol 34, Num 1, pp 48-57, issn 0253-5068, 10 p.Article